Minirin

Central diabetes insipidus. Tab: Primary nocturnal enuresis in childn ≥5 yr. Melt oral lyophilisate: Primary nocturnal enuresis (from ≥6 yr) in patients w/ normal ability to conc urine. Tab/Melt oral lyophilisate: Symptomatic treatment of nocturia in adults associated w/ nocturnal polyuria (eg, nocturnal urine production exceeding bladder capacity). Inj: As diagnostic aid in kidney function exam. Therapeutic control of bleeding & bleeding prophylaxis in connection w/ minor surgical procedures in patients w/ mild haemophilia A & von Willebrand's disease who respond positively to the test dose.

Central diabetes insipidus Tab Adult & childn Initially 0.1 mg tds, then adjusted in accordance w/ the patient's response from 0.2-1.2 mg. For most patients, the maintenance dose is 0.1-0.2 mg tds. Melt oral lyophilisate Initially 60 mcg SL tds, then adjusted in accordance w/ patient response from 120-720 mcg SL daily. For most patients, maintenance dose is 60-120 mcg SL tds. Inj Adult 1-4 mcg (0.25-1 mL) IV once-bd, childn >1 yr 0.4-1 mcg (0.1-0.25 mL) IV once-bd, infant <1 yr 0.2-0.4 mcg (0.05-0.1 mL) IV once-bd. Primary nocturnal enuresis Tab Initially 0.2 mg at bedtime, may be increased to 0.4 mg. Melt oral lyophilisate Initially 120 mcg SL at bedtime, may be increased to 240 mcg SL. Symptomatic treatment of nocturia associated w/ nocturnal polyuria in adult Tab Initially 0.1 mg at bedtime. If dose is insufficiently effective after 1 wk, increase to 0.2 mg & then to 0.4 mg by means of wkly increases. Melt oral lyophilisate Initially 60 mcg SL at bedtime. If dose is insufficiently effective after 1 wk, may be increased up to 120 mcg & subsequently to 240 mcg SL by wkly dose escalations. Renal concentrating capacity test Inj Adult 4 mcg (1 mL) IM/SC, childn >1 yr 1-2 mcg (0.25-0.5 mL) IM/SC, infant <1 yr 0.4 mcg (0.1 mL) IM/SC. Therapeutic control of bleeding & bleeding prophylaxis in Haemophilia A & von Willebrand's disease Inj IV infusion 0.3 mcg/kg body wt over 15-30 min. Adult & childn ≥10 kg Use 50 mL of diluent. Childn ≤10 kg Use 10 mL of diluent. If +ve effect is obtained, the initial dose may be repeated 1-2 times w/ intervals of 6-12 hr.

May be taken with or without food: Take consistently in relation to mealtimes. Melt oral lyophilisate: Administer sublingually.

Hypersensitivity. Habitual or psychogenic polydipsia (urine production >40 mL/kg/24 hr). Known or suspected cardiac insufficiency & other conditions requiring treatment w/ diuretics. SIADH. Hyponatraemia. Moderate & severe renal insufficiency (CrCl >50 mL/min). For haemostatic use: Unstable angina pectoris, decompensated cardiac insufficiency, von Willebrand's disease type II B.

Interrupt treatment during acute illnesses characterised by fluid &/or electrolyte imbalance eg, systemic infections, fever, gastroenteritis. Not to be initiated in patients suffering from other conditions that may increase fluid/electrolyte imbalance. Increased risk for hyponatraemia in patients w/ low serum Na levels & patients w/ high 24-hr urine vol. Caution in patients at risk for increased ICP. Patients w/ urgency/urge incontinence, organic causes for increased micturition frequency or nocturia eg, benign prostate hyperplasia, UTI, bladder stone/tumor, polydipsia & poorly adjusted DM. Limit fluid intake during period of 1 hr before evening dose until at least 8 hr after administration. Frequently monitor serum Na. Concomitant use w/ drugs known to induce SIADH eg, TCAs, SSRIs, chlorpromazine & carbamazepine; NSAIDs. Pregnancy & lactation. Occurrence of hyponatraemia in elderly >65 yr. Not to be initiated in the elderly. Tab: Should not be taken by patients w/ rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Inj: Very young childn. Renal conc capacity testing in childn <1 yr should be performed only in hospital & under careful supervision. Limit fluid intake to max 0.5 L from 1 hr before until 8 hr after administration. In haemostatic use, avoid fluid overload in patient taking diuretics.

Headache. Tab/Melt oral lyophilisate: Adult: Hyponatraemia; dizziness; HTN; nausea, abdominal pain, diarrhoea, constipation, vomiting; bladder & urethral symptoms; oedema, fatigue. Inj: At high doses: Fatigue; transient fall in BP w/ reflex tachycardia & facial flushing administration time. Stomach pain, nausea.

Additive antidiurectic effect w/ substances known to induce disturbed ADH-secretion eg, TCAs, SSRIs, chlorpromazine, carbamazepine; some antidiabetics of sulphonylurea group (chlorpropamide). Tab/Melt oral lyophilisate: Induced water retention/hyponatraemia w/ NSAIDs. Increased plasma conc w/ loperamide. Decreased absorption w/ dimeticone. Tab: Decreased extent & rate of absorption w/ food intake.

Antidiuretics / Haemostatics

H01BA02 - desmopressin ; Belongs to the class of vasopressin and analogues. Used in posterior pituitary lobe hormone preparations.

P₁S₁S₃